Expertise and capabilities
The rational design of new drug candidates relies on optimising many factors including potency and selectivity, synthetic tractability, safety, and pharmacokinetic properties to ensure safe and efficacious exposure profiles and convenient dosing regimens.
This iterative optimisation process focuses on the critical interplay between chemical structure, biological activity, and biodistribution properties to identify and progress drug candidates that are well-positioned for further development.
The CDCO aims to fill a critical gap in drug discovery by providing translational expertise on absorption, distribution, metabolism and excretion (ADME) and pharmacokinetic (PK) properties. Identifying ADME and PK liabilities during drug discovery is essential to guide appropriate structural modifications and identify strategies to mitigate risks during development. The CDCO’s involvement in drug discovery and development projects spans the period of “hit-to-lead” identification through to selection of a preclinical drug candidate.
We use a range of in silico, in vitro and in vivo methods to characterise the critical parameters needed to inform drug candidate optimisation and progression.